Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHILL: QEL-005 in dcSSc and D2TRA
NCT07473154Phase 2Recruiting
- Sponsor
- Quell Therapeutics
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Regulatory T Cells (Tregs), CAR-T Cells
- Countries
- 3
01
Overview
A Phase 2 trial of QEL-005 in systemic sclerosis (SSc), rheumatoid arthritis (RA), sponsored by Quell Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
QEL-005
03
Conditions
systemic sclerosis (SSc)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07473154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473154.